PFE Stock UPDATES Pfizer Inc (PFE) 29.92 09/15/2014 22:35:20

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pfizer Inc (PFE) 29.92 $PFE

Most active New York Stock Exchange-traded stocks
AP - Mon Sep 15, 5:03PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:

Final Glance: Pharmaceuticals companies
AP - Mon Sep 15, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:

Watch for Pfizer to Potentially Pullback After Gaining 1.60% Yesterday
Comtex SmarTrend(R) - Mon Sep 15, 3:46PM CDT
Pfizer (NYSE FE) traded in a range yesterday that spanned from a low of $29.38 to a high of $29.92. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $29.64 on volume of 22.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Nasdaq Underperforms As Leading Growth Stocks Take Heat
at Investor's Business Daily - Mon Sep 15, 10:49AM CDT
The Dow Jones industrial average and S&P 500 held up well Monday, but the Nasdaq took a hit ahead of Tuesday's start of a two-day Federal Reserve meeting. The Nasdaq slumped 1.1%, weighed down by software and solar names. The Dow edged higher, helped...

Early Glance: Pharmaceuticals companies
AP - Mon Sep 15, 9:37AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:

Market Maker Surveillance Report. PFE, QCOM, CSCO, MSFT, ORCL, AMD, Highest Net Sell Volume and Negative Price Friction For Friday, September 12th 2014
M2 - Mon Sep 15, 2:59AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4813 companies with "abnormal" market making, 1557 companies with positive Friction Factors and 3492 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Friday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Pfizer Inc (NYSE FE), Qualcomm Inc (NASDAQ:QCOM), CISCO SYSTEMS INCORPORATED (NASDAQ:CSCO), MICROSOFT CORPORATION (NASDAQ:MSFT), Oracle Corp (NYSE:ORCL), Advanced Micro Devices Inc (NYSE:AMD). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Midday Glance: Pharmaceuticals companies
AP - Fri Sep 12, 12:20PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:

Pfizer (PFE) Approaches New Downside Target of $29.16
Comtex SmarTrend(R) - Fri Sep 12, 11:41AM CDT
Shares of Pfizer (NYSE FE) opened today below their pivot of $29.52 and have already reached the first level of support at $29.39. Analysts will be watching for a cross of the next downside pivot targets of $29.16 and $28.80.

Trading Guidelines for J&J, Merck, Pfizer, 8 Other Drug Companies
at The Street - Fri Sep 12, 10:32AM CDT
Here are some numbers to help investors make prudent decisions when allocating cash to 11 big-cap pharmaceutical companies.

Study Results, New Collaboration, Drug Designation, Technical Update, and Completion of Transaction - Research Reports on Gilead, AbbVie, Pfizer, United Therapeutics and Brookdale
PR Newswire - Fri Sep 12, 8:10AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV), Pfizer Inc. (NYSE: PFE), United Therapeutics Corporation (NASDAQ: UTHR) and Brookdale Senior Living, Inc. (NYSE: BKD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6426-100free.

Global Moderate Psoriasis Therapeutics Pipeline Report 2014 - 17 Companies & 23 Drug Profiles
M2 - Fri Sep 12, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jn2cxm/moderate) has announced the addition of the "Moderate Psoriasis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Johnson & Johnson - Boehringer Ingelheim GmbH - Amgen Inc. - Eli Lilly and Company - Merck & Co., Inc. - AbGenomics International, Inc. - ApoPharma Inc. - Novartis AG - Pfizer Inc. - OPKO Health, Inc. - Idera Pharmaceuticals, Inc. - Almirall, S.A. - Syntrix Biosystems, Inc. - Vascular Biogenics Ltd. - Hy BioPharma Inc. - GlycoMar Limited - Convoy Therapeutics, Inc. Drug Profiles - brodalumab - ixekizumab - secukinumab - tildrakizumab - LAS-41008 - adalimumab biosimilar - baricitinib - AbGn-168H - VB-201 - lunacalcipol - aminopterin sodium - HBP-347 - orilotimod - BI-655066 - IMO-8400 - PF-04965842 - MOL-4249 - AVX-001 - AMG-811 - guselkumab - AKP-11 - cyclosporine - GLY-2028 For more information visit http://www.researchandmarkets.com/research/jn2cxm/moderate

Spinal Muscular Atrophy (SMA) Therapeutics Pipeline Review 2014 - 17 Companies & 27 Drug Profiles
M2 - Fri Sep 12, 3:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r5vn8b/spinal_muscular) has announced the addition of the "Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Muscular Atrophy (SMA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Genzyme Corporation - F. Hoffmann-La Roche Ltd. - Isis Pharmaceuticals, Inc. - Pfizer Inc. - Zambon Company S.p.A. - Paratek Pharmaceuticals, Inc. - Cytokinetics, Inc. - Neurotune AG - Trophos SA - Nexgenix Pharmaceuticals, LLC - Genethon - Vybion, Inc. - OrphageniX, Inc. - Retrophin, LLC - Neurodyn Inc. - GMP-Orphan SAS - Cellular Biomedicine Group, Inc. Drug Profiles - olesoxime - ISIS-SMNRx - PF-06687859 - RG-7800 - Gene Therapy to Activate SMN for Spinal Muscular Atrophy - AAV9-SMN Gene Therapy - tirasemtiv - PTK-SMA-2 - NXD-30001 - DNA Oligonucleotides for Spinal Muscular Atrophy - RE-003 - Gene Therapy for Spinal Muscular Atrophy - ND-602 - Antisense Oligonucleotide for Spinal Muscular Atrophy and Myotonic Dystrophy - Motor Neuron Precursor Cells - Small Molecule to Activate SMN Protein for Spinal Muscular Atrophy - Agrin Biologic For SMA - sodium phenylbutyrate - Small Molecules for CNS Disorders - PMO-25 - Synthetic Peptides for Central Nervous System Disorders - BBrm-01 - Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy - Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy - INT-41 - Antisense Oligonucleotides for Spinal Muscular Atrophy - ZP-037 For more information visit http://www.researchandmarkets.com/research/r5...l_muscular

5 Toxic Stocks to Sell Now
at The Street - Thu Sep 11, 12:50PM CDT
It's time to unload these stocks from your portfolio.

Why I'd Avoid Pfizer Inc. Stock Despite the Dividend
George Budwell, The Motley Fool - Motley Fool - Thu Sep 11, 11:28AM CDT
Dividend stocks tend to be strong performers over the long term due to their ability to harness the awesome power of compounding returns. Even so, investors should always bear in mind that not all dividend stocks are good investments, even when they...




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 17

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading
AIC Hotel Group's 11 Awards Test Resort Market Reach

Updated Category News Views 89

Eleven Trophies, Four Properties, One Useful Signal Hospitality awards can be a lot of polished brass and very little cash flow, but this batch is substantial enough to deserve a hard look. AIC Hotel Group collected 11 honors spanning Condé Nast Traveler's 2026 Readers' Choice Awards, Travel Weekly's 2026 Magellan Awards, and Good Housekeeping's 2027 Travel Awards. The...

Continue Reading
Saban Center Partnership Gives Health Learning a Lift

Updated Category News Views 45

A dinosaur race may sound like pure kid bait, but the underlying idea is sturdier than that. Cardiac Solutions and the Seale family are backing an interactive health-and-performance exhibit at Tuscaloosa’s planned Saban Center, a project intended to turn questions about movement, fitness, heart rate and oxygen levels into something children can actually touch, test and...

Continue Reading
RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 138

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
FLX Opens a New Door to Pre-IPO Deal Flow for Advisors

Updated Category News Views 126

Private-market chatter has been leaking past the velvet rope for years, and advisors are sick of learning about it after a client already has a pitch deck in hand. FLX Networks is responding to that irritation by letting its eligible advisor and wealth-management members review select pre-IPO opportunities shared by other members. Announced November 19, 2026, the move is...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 164

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Intel Investors Face January 12 Lead Plaintiff Deadline

Updated Category News Views 110

A Narrow Calendar Window Has Opened Intel holders have another legal deadline to put on the fridge, and this one is not a casual housekeeping item. A securities class action has been filed in the Northern District of California on behalf of investors who bought or acquired Intel shares between July 23, 2026, and October 29, 2026. The deadline to seek appointment as lead...

Continue Reading
CMA Wins Spotlight Greenberg Traurig’s Music Bench

Updated Category News Views 81

Four trophies on one awards night can say plenty about the machinery behind a music career, even if nobody should confuse a CMA acceptance speech with a balance-sheet event. Greenberg Traurig’s entertainment practice is celebrating client wins at the 60th annual CMA Awards, held Nov. 18, 2026: three honors tied to Miranda Lambert and one for Brooks & Dunn. For investors...

Continue Reading
Caregiver Strategy Puts a Hard Truth on the Table Today

Updated Category News Views 47

Sixty-three million people carrying care responsibilities is not a side issue; it is a national load-bearing wall. The 2026 National Strategy to Support Family Caregivers arrives with that reality plainly in view, and frankly, it is overdue for the country to treat family care as core infrastructure rather than a private household problem somebody is expected to absorb...

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 118

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading

Top 5 Most Recently Viewed Articles

Eastman Chemical’s Stock Surge Marks a Turning Point for Investors

Updated Category News Views 82

Eastman Chemical's Stock Hits New Heights Eastman Chemical Company (NYSE: EMN) has recently reached an impressive milestone, with its stock price climbing to a 52-week high of $107.14. This significant price point reflects growing investor confidence and a positive market outlook for the company. With a remarkable 34.6% increase over the past year, Eastman Chemical has...

Continue Reading
BOS Expands Automation Solutions with New System Orders

Updated Category News Views 270

BOS Secures New Orders for Robotic Solutions BOS Better Online Solutions Ltd. (NASDAQ: BOSC), renowned for its expertise in supply chain technologies, has recently announced a significant milestone. The company secured orders for two innovative robotic packing and palletizing systems aimed at enhancing efficiency in food manufacturing. Details of the New Orders These new...

Continue Reading
Amazon's Cloud and AI Strategy Set to Shape Future Growth

Updated Category News Views 260

Overview Amazon.com, Inc. (NASDAQ: AMZN) plays a crucial role in the realms of e-commerce, cloud computing, digital streaming, and artificial intelligence. Recent analyses from respected financial institutions provide a thorough insight into Amazon's market performance, strategic initiatives, and its future outlook. This article brings together these evaluations, zeroing...

Continue Reading
WTW's Strategic Acquisitions: A Leap into the Future of Insurance

Updated Category News Views 211

WTW Expands Through Innovative Acquisitions Willis Towers Watson Public Ltd., known as WTW, is making headlines with its ambitious strategy to enhance its technology-enabled insurance and workplace benefits services. By announcing two consequential acquisitions, WTW aims to broaden its reach in the middle market while modernizing its client interactions significantly....

Continue Reading
Genmab's Share Buy-Back Program: Recent Transaction Details

Updated Category News Views 173

Introduction to Genmab Genmab A/S is a pioneering biotechnology company based in Copenhagen, Denmark, dedicated to improving the lives of patients through innovative antibody therapies. Founded in 1999, Genmab has continuously worked on developing groundbreaking antibody technology platforms, aiming to advance treatment for serious diseases such as cancer. Share Buy-Back...

Continue Reading